Abstract #1976

19F MR characterization of teriflunomide, a fluorinated drug indicated in Multiple Sclerosis

Christian Prinz¹, Jason M. Millward¹, João dos Santos Periquito¹, Ludger Starke¹, Paula Ramos Delgado¹, Stefanie Muenchberg¹, Andreas Pohlmann¹, Thoralf Niendorf^1,2, and Sonia Waiczies¹

¹Berlin Ultrahigh Field Facility, Max Delbrueck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany, ²Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max Delbrueck Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Teriflunomide is an anti-inflammatory drug indicated for the treatment of Multiple Sclerosis (MS). This disease presents with a wide spectrum of symptoms and available drugs have different effects, thereby posing a major treatment challenge. Due to its three fluorine atoms, teriflunomide can be detected non-invasively by fluorine-19 (¹⁹F) magnetic resonance. The objective of this work is to characterize the ¹⁹F MR properties of teriflunomide in order to adapt MR sequences for in vivo measurements. Here, we studied the relaxation times of teriflunomide and their modifications as a result of concentration, pH and temperature changes.

This abstract and the presentation materials are available to members only; a login is required.

Join Here